Scarica l'app Stockscreener
14.14
1.19%
-0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.31
Aprire:
$14.25
Volume 24 ore:
1.51M
Relative Volume:
1.11
Capitalizzazione di mercato:
$11.77B
Reddito:
$3.85B
Utile/perdita netta:
$667.93M
Rapporto P/E:
21.52
EPS:
0.657
Flusso di cassa netto:
$142.30M
1 W Prestazione:
+0.43%
1M Prestazione:
+6.96%
6M Prestazione:
-0.84%
1 anno Prestazione:
+1.07%
Intervallo 1D:
$14.06
$14.33
Intervallo di 1 settimana:
$14.00
$14.33
Portata 52W:
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.14 | 11.91B | 3.85B | 667.93M | 142.30M | 0.657 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-12-19 | Downgrade | Nomura | Buy → Neutral |
| 2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
| 2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-30 | Iniziato | JP Morgan | Underweight |
| 2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Ripresa | BofA Securities | Neutral |
| 2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-09-18 | Aggiornamento | Investec | Sell → Hold |
| 2020-01-28 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-27 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2019-06-20 | Iniziato | Deutsche Bank | Hold |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
| 2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
| 2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
| 2017-07-28 | Downgrade | CLSA | Underperform → Sell |
| 2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
| 2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
US-India Trade Deal: Indian ADRs Jump Up To 6.75%; Sensex & Nifty Set For Rally - samco.in
Dr. Reddy’s Labs ADR earnings beat by $14.36, revenue topped estimates - Investing.com Australia
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y - Finviz
Dr. Reddy’s Strong Base Business, Aided by Partnerships and New Launches, Offsets North America Drag - Morningstar
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips By Investing.com - Investing.com India
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips - Investing.com
Infosys ADR stock jumps over 10% on Wall Street after IT major revises revenue guidance for FY2026 — Details here - Mint
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Dr. Reddy’s Labs ADR: Quiet Rally, Firm Fundamentals – Is RDY Still Undervalued? - AD HOC NEWS
HDFC Bank share price drops almost 4% in 2 days after Q3FY26 business update - Mint
Infosys ADR Surges 15% Suddenly! Expert Feroze Azeez Reveals The Shocking Derivative Secret! - Whalesbook
Infosys trading: Infosys ADR 40% spike traced to data error, algo trading, says report - Business Today
What does Infosys ADR stock rally on the NYSE mean for Infosys shares on the NSE, BSE? - livemint.com
Infosys ADR stock jumps over 56% over strong volumes on US stock market today — Details here - livemint.com
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens - ChartMill
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
Validea's Top Health Care Stocks Based On Peter Lynch12/15/2025 - Nasdaq
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Sahm
Asian Equities Traded in the US as ADRs Fall in Thursday Trading - 富途牛牛
Kelkar & Mehta: Justice is a constitutional promise: Uphold it by giving alternative dispute resolution a chance - Mint
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History - The Economic Times
Asian ADRs Nudge Higher As Tech And Pets Take The Lead - Finimize
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires New Shares in Full Truck Alliance Co. Ltd. Sponsored ADR $YMM - Defense World
Asian ADRs Dip In The US As Volatility Continues - Finimize
Asian ADRs Kick Off The Week With Broad Gains - Finimize
Is Zoetis Stock Underperforming the Dow? - Barchart.com
US Stock Market today: Dow Jones, Nasdaq, S&P 500 open higher over improving Fed rate cut bets — Details here - livemint.com
Vise Technologies Inc. Makes New Investment in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Migdal Insurance & Financial Holdings Ltd. Sells 20,000 Shares of Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asia’s Biggest US-Listed Stocks Saw Mixed Results Today - Finimize
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - Finviz
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):